GlassScriptPhysician profile
Premalatha Nandkumar
NPI 1366471898
$7,537.97
in general payments reported to CMS, 2019-2025
34 companies · $480 in 2025
The $480 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,407 · 2020: $1,283 · 2021: $1,365 · 2022: $1,152 · 2023: $986 · 2024: $865 · 2025: $480.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,243 · Education: $87.57.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,242.92 |
| Education | $87.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,774.05 | 2019-2025 | |
| Novo Nordisk INC | $985.59 | 2019-2025 | Ozempic, Rybelsus, Tresiba |
| Astrazeneca Pharmaceuticals LP | $617.42 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $439.55 | 2019-2025 | |
| Amarin Pharma, INC. | $433.61 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $393.04 | 2021-2024 | |
| Amgen INC. | $381.88 | 2019-2025 | Repatha, Otezla, Evenity |
| Janssen Pharmaceuticals, INC | $361.95 | 2019-2022 | |
| Lilly USA, LLC | $327.55 | 2019-2023 | Mounjaro |
| Sanofi-Aventis U.S. LLC | $237.12 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $226.62 | 2019-2021 | |
| Allergan, INC. | $201.37 | 2019-2020 | |
| Glaxosmithkline, LLC. | $142.72 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Astellas Pharma US INC | $99.68 | 2019-2025 | |
| Azurity Pharmaceuticals, INC. | $98.51 | 2023-2024 | Edarbi, Edarbi, Horizant |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $87.22 | 2019-2024 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.74 | 2021 | |
| Novartis Pharmaceuticals Corporation | $80.13 | 2019-2023 | |
| Abbott Laboratories | $75.84 | 2021-2025 | Freestyle Libre 3 |
| Esperion Therapeutics, INC. | $74.51 | 2020-2024 | Nexletol |
| Biohaven Pharmaceutical Holding Company LTD. | $63.02 | 2022 | |
| Phathom Pharmaceuticals, INC. | $47.51 | 2023-2024 | Voquezna |
| Ironwood Pharmaceuticals, INC | $37.74 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.33 | 2025 | Xifaxan |
| Arbor Pharmaceuticals, INC. | $34.87 | 2019 | |
| Corcept Therapeutics | $32.04 | 2024 | Korlym |
| Jazz Pharmaceuticals INC. | $29.98 | 2021 | |
| Ibsa Pharma INC. | $27.76 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $21.44 | 2023 | Quviviq |
| Paratek Pharmaceuticals, INC. | $21.03 | 2023 | Nuzyra |
| Lexicon Pharmaceuticals, INC. | $19.18 | 2024 | |
| Philips North America LLC | $16.19 | 2020 | |
| Amag Pharmaceuticals, INC. | $15.31 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $13.47 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Premalatha Nandkumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.